SynVaccine
Design and Construction of Viral-based Products
Company Overview
Snapshot
Founded in July 2013 by Tamir Tuller and Tuval Ben Yehezkel, SynVaccine operates with 1–10 employees. The company has raised $1.76M across two funding rounds from six investors. In November 2017, SynVaccine secured funding from A2Z Venture Partners and Pix Vine Capital.
Business overview
SynVaccine develops a CAD/CAM platform for designing and fabricating designer viruses for biotechnology. The company integrates synthetic biology, virology, bioinformatics, engineering, and robotics to create viruses for new vaccine development. Its technology focuses on the safe design and fabrication of viral genomes, aiming to overcome limitations of naturally occurring or traditionally developed viruses. SynVaccine operates within the Health Tech & Life Sciences sector, specifically targeting Pharmaceuticals and Biotechnology markets.
Strategic signal
In November 2017, SynVaccine raised $1.7 million, signaling investor confidence in its innovative approach to vaccine development. This funding round, which included participation from A2Z Venture Partners and Pix Vine Capital, highlights the potential for.
Log in to access full profile ›Company Intelligence Q&A
- When was SynVaccine founded and by whom?
- SynVaccine was founded in July 2013 by Tamir Tuller and Tuval Ben Yehezkel.
- What is SynVaccine's core technology?
- SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology, utilizing synthetic biology, virology, bioinformatics, engineering, and robotics.
- What was a significant funding event for SynVaccine?
- In November 2017, SynVaccine raised $1.7 million in a funding round that included investors such as A2Z Venture Partners.
- Which organizations contributed to the foundational research for SynVaccine's technology?
- SynVaccine's technology is based on commercialized research from Tel Aviv University and Weizmann Institute of Science, led by.
- What is the primary application of SynVaccine's viral-based products?
- SynVaccine's viral-based products are primarily used to develop new vaccines, with a focus on overcoming limitations of viruses found in nature or developed through traditional technologies.